Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging
Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging
复制标题
DOI：
10.2165/00002512-200118100-00001
复制
发表时间：
2001-01-01
期刊：
影响因子：
2.8
通讯作者：
Lipton, SA
中科院分区：
文献类型：
--
作者：
Le, DA;Lipton, SA
N-甲基-D-天冬氨酸（NMDA）受体复合物是谷氨酸受体的一种亚型，其功能障碍涉及许多与衰老相关的神经系统疾病，包括慢性疼痛、抑郁症、中风和帕金森病。使用NMDA受体拮抗剂的多项临床试验已经中止，主要是由于这些药物在脑中浓度达到足够水平之前发生的严重拟精神不良反应。在这篇综述中，我们提出的证据表明，临床上更安全的NMDA拮抗剂，如美金刚和硝酸甘油。和组合药物硝基-美金刚，作为治疗神经变性疾病的药物是有希望的。
The N-methyl-D-aspartate (NMDA) receptor complex is a subtype of glutamate receptor and its dysfunction is involved in many neurological disorders associated with aging, including chronic pain, depression, stroke and Parkinson's disease. Multiple clinical trials using NMDA receptor antagonists have been aborted mainly due to the severe psychomimetic adverse effects of these drugs that occur before concentrations can reach an adequate level in the brain. In this review, we present the evidence that clinically safer NMDA antagonists such as memantine and nitroglycerin., and the combination drug nitro-memantine, are promising as drugs in treating neurodegenerative diseases.